◀ Back to EPHB2
EPHB2 — PAM
Text-mined interactions from Literome
Slack et al., Eur J Immunol 2007
:
Conversely,
ERK activation in
response to the TLR2 agonist
Pam3Cys is completely MyD88 dependent and unaffected by Syk deficiency
Adhikary et al., J Leukoc Biol 2008
(Corneal Diseases...) :
We found that S. aureus and
Pam3Cys stimulate phosphorylation of JNK, p38 MAPK, and
ERK within 4 h and that blockade of JNK, but not p38 or ERK phosphorylation, had an inhibitory effect on IkBalpha degradation and CXC chemokine production
Nyugen et al., J Clin Immunol 2010
(Bacterial Infections) :
In this study, we have identified and compared four subpopulations of monocytes ( CD14 ( ++ ( high ) ) CD16 ( - ), CD14 ( + ( low ) ) CD16 ( - ), CD14 ( ++ ( high ) ) CD16 ( + ), and CD14 ( + ( low ) ) CD16 ( + ) ) in the peripheral blood of young and aged subjects with regard to their numbers, cytokine production, TLR expression, and phosphorylation of
ERK1/2 in
response to
pam3Cys a TLR-1/2 ligand
Beaulieu et al., Blood 2011
:
Using Meg-01 cells and mouse megakaryocytes, we found that NF?B,
ERK-MAPK , and PI3K/Akt pathways, known downstream pathways of TLRs, are
activated by
Pam3CSK4 , a TLR2-specific ligand
Foley et al., J Biol Chem 2012
(MAP Kinase Signaling System) :
Pam3Cys , a specific TLR2 agonist,
stimulated phosphorylation of JNK,
ERK , and p38, but only JNK and ERK inhibition blocked Pam3Cys stimulated chemotaxis